(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 September 2022 (09.09.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/186876 A1

(51) International Patent Classification:
A61P 25/00 (2006.01) *C07C 51/47* (2006.01)
A61K 33/44 (2006.01) *A61K 47/12* (2006.01)

(21) International Application Number:
PCT/US2021/063977

(22) International Filing Date:
17 December 2021 (17.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/154,899 01 March 2021 (01.03.2021) US
PCT/US2021/062908
10 December 2021 (10.12.2021) US

(71) Applicant: **PHARMZANDIA CORPORATION** [US/US]; 1000 N Green Valley Pkwy., #440-339, Henderson, Nevada 89074 (US).

(72) Inventor: **BUTZLOFF, Peter**; c/o Rimon, PC, 800 Oak Grove Avenue, Suite 250, Menlo Park, California 94025 (US).

(74) Agent: **HAYDEN, Robert** et al.; Rimon PC, 800 Oak Grove Avenue, #250, Menlo Park, California 94025 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) **Title:** FULLERENE GABA DOPA AND METHODS




FIG. 5

(57) **Abstract:** A novel dual neurotransmitter nanoparticle composition is provided to store and transport protons and cations into neural cell membranes and to disassemble salt-bridge stabilized toxic protein plaques. These properties function to mitigate cognitive deficits in neurological diseases such as Parkinson's disease and Alzheimer's disease, as well as to reduce the severity of Inflammatory Bowel Syndrome, and aging related reactive oxygen species damage by promoting the sequestration and termination of free radicals and reactive oxygen species. The composition comprises C60 bonded to one or more gamma amino butyric acid molecules and one or more molecules of either levodopa or dopamine. The composition can be produced at low temperatures through reactive shear milling. This composition therapeutically improves and prophylactically preserves cognitive performance, memory, and mental acuity on aging to promote mental performance and health-span improvement.

WO 2022/186876 A1